At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 584 enrolled
Drug / intervention
Cethromycin +1 moredrug
Likely dose
Cethromycin 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults
In Brief
A Phase 3 clinical trial evaluating Cethromycin and Clarithromycin for Pneumonia. Completed, enrolled 584 participants across 3 sites.
Detailed Summary
The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedJun 2006
Primary CompletionOct 2007
TodayJul 2026
First PostedJun 13, 2006
Enrollment StartDec 1, 2005
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.1 years ago
Interventions
Cethromycindrug
Cethromycin 300 mg once per day (QD) for 7 days, administered orally
Clarithromycindrug
Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally